|
gptkbp:instanceOf
|
gptkb:small_molecule
gptkb:drug
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XX65
|
|
gptkbp:brand
|
gptkb:Tibsovo
|
|
gptkbp:CASNumber
|
1448347-49-6
|
|
gptkbp:developer
|
gptkb:Agios_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
93 hours
|
|
gptkbp:hasMolecularFormula
|
C28H22ClF3N6O3
|
|
gptkbp:hasSMILES
|
CC1=NC2=C(N1C3=CC=CC=C3)C(=NC(=N2)C4=CC=C(C=C4)Cl)C5=CC(=C(C=C5)F)C(=O)N
|
|
gptkbp:KEGGID
|
D11041
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
IDH1 inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
582.96 g/mol
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL3545110
gptkb:DB12033
89683826
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
QT prolongation
arthralgia
leukocytosis
prolonged QT interval
differentiation syndrome
|
|
gptkbp:synonym
|
gptkb:AG-120
|
|
gptkbp:target
|
gptkb:IDH1
|
|
gptkbp:UNII
|
6Z5B6HVF6O
|
|
gptkbp:usedFor
|
gptkb:acute_myeloid_leukemia
cholangiocarcinoma
|
|
gptkbp:bfsParent
|
gptkb:TIBSOVO
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ivosidenib
|